09:02 AM EDT, 03/13/2025 (MT Newswires) -- Mainz Biomed ( MYNZ ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.

The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.

Under the agreement, Mainz Biomed ( MYNZ ) will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.

The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.

MYNZ shares were 0.8% higher in recent premarket activity.